靶向CCR4的CAR T细胞在体外和体内选择性清除人调节性T细胞
调节性T细胞(Treg)维持免疫耐受但抑制抗肿瘤免疫,CCR4高表达于瘤内Treg。研究评估靶向CCR4的CAR T细胞(CCR4-CART)在患者胸水、肺癌肿瘤消化液及人源化小鼠中清除Treg的效果。结果显示CCR4-CART几乎完全清除Treg,保留CD8+ T细胞,单次输注在体内实现近完全Treg清除,支持其临床开发。
要点
- CCR4-CART在患者样本中几乎完全清除Treg,同时保留CD8+ T细胞。
- 人源化小鼠中单次输注CCR4-CART实现近完全Treg清除。
- CCR4-CART可能成为选择性调节Treg的有效策略,需进一步临床研究。
核心结论
- CCR4-CART可在体外和体内选择性且有效地清除人Treg,支持进一步临床研究。
研究设计与样本
- 研究评估先前为T细胞恶性肿瘤开发的人特异性CCR4-CART,在患者来源恶性胸腔积液、肺癌肿瘤消化液及人源化小鼠中测试Treg清除效果。
主要发现
- 在患者来源恶性胸腔积液和肺癌肿瘤消化液中,CCR4-CART几乎完全清除Treg,同时清除少量CCR4+CD4+非Treg,但保留CD8+ T细胞。
- 在人源化小鼠体内,单次剂量CCR4-CART导致Treg近完全清除。
临床怎么用
- CCR4-CART可能作为选择性Treg调节策略,用于增强抗肿瘤免疫,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Regulatory T cells (Tregs) are essential for maintaining immune tolerance but also contribute to immune suppression within the tumor microenvironment (TME), dampening antitumor immunity in hematologic and solid tumors. As such, strategies aimed at depleting Tregs or reducing their suppressive activity are of great clinical interest. CC chemokine receptor 4 (CCR4) is highly expressed on intratumoral Tregs and mediates Treg migration into the TME. Although current therapies targeting CCR4 using monoclonal antibodies have shown some Treg depletion in clinical trials, their clinical efficacy has been limited. We therefore tested whether chimeric antigen receptor (CAR) T-cell (CART) therapy could be used to deplete Tregs. We evaluated human-specific CCR4-directed CARTs (CCR4-CARTs) previously developed for T-cell malignancies and determined whether these CARTs could deplete human Tregs ex vivo and in vivo. In patient-derived malignant pleural effusions and lung cancer tumor digests, CCR4-CARTs almost completely depleted Tregs, along with a small population of CCR4+CD4+ non-Tregs, while sparing CD8+ T cells. When tested in vivo in humanized mice, a single dose of CCR4-CARTs led to nearly complete Treg depletion. These findings support the potential of CCR4-CARTs as a selective and effective approach to Treg modulation and warrant further clinical investigation.
引用
- Tilsed CM, Fong KP, Shi X, et al. CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo. Blood Adv. 2026. PMID: 41370186. doi:10.1182/bloodadvances.2025017573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。